A significant paradigm shift is underway in the treatment of gastrointestinal and metabolic disorders, heralded by the advent of a novel therapeutic class: ileal bile acid transporter (IBAT) inhibitors. This innovative approach targets a fundamental physiological process, offering new hope to patients battling the debilitating symptoms of cholestatic liver diseases. By intervening directly in...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek